Skip to content
Adagio Medical logo

Adagio Medical

ADGM

Adagio Medical is a medical device company specializing in the development and commercialization of advanced catheter-based technologies for treating cardiac arrhythmias.

Market cap
$10.7M-49.2%

Table of contents

Earnings

Next report

Aug 12, 2026 (In 2 weeks)
EPS estimate-$0.31

Competitors

Profile

Adagio Medical is a medical device company specializing in the development and commercialization of advanced catheter-based technologies for treating cardiac arrhythmias. Its core value proposition is the proprietary Ultra-Low Temperature Ablation (ULTA) platform, which uses near-critical nitrogen to create deep, durable lesions in heart tissue to treat complex conditions like ventricular tachycardia. The company's technology is designed to overcome the limitations of traditional radiofrequency ablation by providing better tissue penetration and procedural stability without the need for irrigation.

Competitive position

Adagio is an emerging innovator in the electrophysiology market, holding FDA Breakthrough Device Designation for its vCLAS system and targeting the underserved ventricular tachycardia market.

GeographiesUnited States, European Union, Canada
Customer segmentsHealthcare Providers, Specialized Clinics
Business modelMedical Device Manufacturing, Direct Sales
SuppliersSpecialized medical-grade nitrogen suppliers, Catheter component manufacturers, Electronic console assembly partners
CustomersElectrophysiologists, Hospital procurement departments, Cardiac care units
Listed2024
CEOTodd Usen
FilingsSEC EDGAR

Questions, answered.

What is Adagio Medical's market cap?
Adagio Medical (ADGM) has a market capitalization of $10.7M and trades on XNAS.
Who are Adagio Medical's competitors?
Adagio Medical's key competitors include Medtronic, Boston Scientific, Johnson & Johnson, and others. These companies compete in similar markets and product categories.
Where is Adagio Medical headquartered?
Adagio Medical is headquartered in United States of America. It has been publicly traded since 2024.